| In partnership with |  |
| Good day, 360! | Here are some of our top movers today. And if you love LOTTOS (0dte trades), check out this flash special happening now. Be the most excited trader on the Street! | | FOCUS LIST🔎 | TECX - Up over 55% in pre after announcing positive interim data from Phase 1b trial for TX45 in patients with group 2 Pulmonary Hypertension in HFpEF | KZIA - Up over 70% in pre after announcing the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer | PLRZ - Up over 15% in pre after announcing filing of divisional patent application for Its innovative Trap & Target™ (T&T) intranasal drug delivery platform | | In partnership with | |
| The future of moving starts here. | | Where you live shapes how you live. We make moving simpler, clearer, and better with tools that guide you from exploring new places to settling in. | Become A Shareholder | Read the Offering information carefully before investing. It contains details of the issuer's business, risks, charges, expenses, and other information, which should be considered before investing. Obtain a Form C and Offering Memorandum at https://wefunder.com/lookyloo | |
|
| | HOTLIST🔥 | TECX - Up over 55% in pre after announcing positive interim data from Phase 1b trial for TX45 in patients with group 2 Pulmonary Hypertension in HFpEF | Tectonic Therapeutic Inc. (TECX) is a clinical stage biotechnology company that focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). | In the pre-market this morning, the company announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. | Highlights include: | TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trial Interim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe disease TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune related reactions
| Shares of TECX traded up over 55% in the pre-market in reaction to the news. | | The $32 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $37, $38, $40, $41, $42, and then the pre-market high at $44.15. Beyond that, $48 and $52 come into play. | Below $32, targets to the downside are $30, $28, and then a gap fill at $25.72. | | KZIA - Up over 70% in pre after announcing the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer | Kazia Therapeutics Limited (KZIA) operates as an oncology-focused biotechnology company. | In the pre-market this morning, the company announced the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. | This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer. | The ABC-Pax (Advanced Breast Cancer – Paxalisib) study is the first known trial conducted to assess the safety and efficacy of paxalisib in combination with KEYTRUDA® (pembrolizumab) or LYNPARZA® (olaparib) in women with triple negative breast cancer. | ABC-Pax is a multi-centre, open-label phase 1b study that will enroll 24 patients from top cancer centres in Queensland, Australia and patients will receive the combination therapy for up to 12 months. | Shares of KZIA traded up over 70% in the pre-market in reaction to the news. | | The first target for bulls is $2.72 and then the pre-market high at $2.77. Beyond that, $2.80, $3.10, $3.50 and $4.20 come into play. | Below $2.72, targets to the downside are $2.43, $2.27, $2, $1.82, $1.69 and then a gap fill at $1.38. | | LottoX: Today At 12:30PM ET | Bring your appetite to learn! | MEMBER-ONLY LottoX session with JW @ 12:30PM ET! | | JW's already identified 3 high-conviction trades… | He'll reveal everything AND teach + release another upon becoming a LottoX member. | (Flash Special Ending in 3…2..) | →Strictly Limited 60% Discount← |
|
| | PLRZ - Up over 15% in pre after announcing filing of divisional patent application for Its innovative Trap & Target™ (T&T) intranasal drug delivery platform | Polyrizon Ltd. (PLRZ) is a biotech company that engages in the development of medical device hydrogels in the form of nasal sprays in Israel. | In the pre-market this morning, the company announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. | This application focuses exclusively on protecting the Company's advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company's recently announced U.S. patent application which encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery. | Shares of PLRZ traded up over 15% in the pre-market in reaction to the news. | | The $1.45 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1.55, $1.66 and then the pre-market high at $1.73. Beyond that, $1.80 and $2 come into play. | Below $1.45, targets to the downside are $1.40, $1.35 and then a gap fill at $1.30. | | MARKET NEWS 📰 | | | Don't miss out on our MOBILE ALERTS! Some of these alerts have rocketed 🚀past the MOON 🌝. Text "RAGE" to 1-(888) 487-1534 📲. | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar